Merck's Keytruda Scores Another Regulatory Nod In Canada

Merck & Co Inc.(MRK) said on Monday that its blockbuster cancer drug Keytruda has received yet another approval in Canada.

The drug has been approved as a treatment for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.

TNBC is a destructive subtype of breast cancer with a tendency to spread quickly. In addition, it also characterized by its high recurrence rate within the first five years after diagnosis. Last year, more than 28,000 Canadian women were estimated to have been diagnosed with breast cancer.

The drug generated annual sales of $17.2 billion in 2021 compared to $14.38 billion in the prior year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT